STOCKHOLM, June 2, 2023 /PRNewswire/ -- Medivir AB (NASDAQStockholm:MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide (fostrox) in combination with Keytruda® in the initial dose escalation part (phase 1b) of the company's 1b/2a study in hepatocellular carcinoma (HCC). In the ongoing expansion part of the study (phase 2a) Medivir is focusing on the fostrox and Lenvima combination and intends to explore the possibility of fostrox in a triple combination together with immunotherapy in earlier lines.
Read more at prnewswire.comMedivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
